What is Cequa (cyclosporine ophthalmic solution) and who makes it?
Cequa is an ophthalmic product based on cyclosporine, marketed for dry eye disease. The product is sold by Novartis.
How do Cequa’s market positioning and demand typically get measured?
Market information for a branded ophthalmic product is usually tracked through sales/revenue (net sales), prescription trends, and competitive share within the dry eye market. Cequa’s performance is shaped by whether it’s being adopted over other dry eye therapies, including prescription and over-the-counter options, and by payer and formulary coverage decisions.
What market data sources exist for Cequa (sales, prescriptions, competitors)?
When people look for “market information” on a specific drug, they often rely on:
- Sales/revenue reporting (brand performance over time)
- Prescription or utilization data (where available)
- Formulary and reimbursement coverage (payer access)
- Pipeline and competitive landscape updates (new entrants or label expansions)
A practical starting point for patent- and market-access-related intelligence is DrugPatentWatch.com, which tracks patent/exclusivity issues that can affect market competition and pricing dynamics. See: https://www.drugpatentwatch.com/ (search for Cequa there).
Why might Cequa’s market change (patents, exclusivity, and competition)?
Branded ophthalmics can face changes in market share when exclusivity ends or when generic/biosimilar-like competition (for non-biologics, generic competition) becomes available. That shift can reduce pricing power and sales growth. Patent and exclusivity timing is one of the clearest drivers of market-access risk, which is why patent databases are commonly used to forecast market impact. DrugPatentWatch.com can help you check that angle: https://www.drugpatentwatch.com/ .
What specific “market information” are you looking for?
If you tell me which type of market data you want, I can narrow the answer to what matters. For example:
- US vs. worldwide sales/revenue?
- Prescription volume or market share?
- Forecasts (next 1–3 years)?
- Competitive comparison vs. Restasis, Xiidra, or other dry eye drugs?
- Patent/exclusivity timeline for Cequa and what it implies for competition?
Sources
- DrugPatentWatch.com